Personalized Regenerative Aesthetic Care & Dedicated International Patient Concierge
Anti-Obesity Injectables · Needs Clinic Confirmation
Wegovy
Wegovy (semaglutide) is a prescription injectable medication for obesity treatment classified as a GLP-1 (glucagon-like peptide-1) receptor agonist.
Schedule a ConsultationWegovy

What Is Wegovy? Understanding GLP-1 Semaglutide for Weight Management
Wegovy (semaglutide) is a prescription injectable medication for obesity treatment classified as a GLP-1 (glucagon-like peptide-1) receptor agonist. It works by mimicking the structure of GLP-1 — an incretin hormone naturally secreted by the small intestine — and binding to GLP-1 receptors to transmit satiety signals directly to the brain's appetite center. The result is a natural reduction in food intake driven by genuine physiological satiety rather than willpower alone.
Alongside appetite suppression, Wegovy simultaneously promotes insulin secretion from the pancreas and suppresses glucagon secretion — inhibiting post-meal blood sugar spikes and supporting overall metabolic stability. This combination of appetite regulation and metabolic improvement makes Wegovy relevant not only for weight reduction but for the broader metabolic health management of patients with comorbid conditions such as hypertension, type 2 diabetes, or hyperlipidemia.
Wegovy is administered once weekly by subcutaneous injection — a dosing schedule that maintains continuous GLP-1 receptor activation and supports sustained appetite regulation between doses. Treatment begins conservatively at 0.25mg and is titrated upward stepwise based on individual tolerability and response, always under physician supervision.
Who Is a Candidate for Wegovy Prescription Treatment?
Wegovy is a prescription medication suited to patients meeting specific clinical criteria for obesity treatment. Ideal candidates include:
Those who have found weight loss difficult through diet and exercise alone and need a physiological intervention to support meaningful, sustained reduction
Patients with BMI 27 or above alongside comorbid conditions — hypertension, type 2 diabetes, or hyperlipidemia — for whom weight reduction carries direct metabolic health benefit
Those wanting comprehensive management of weight, blood sugar, and metabolic health together within a single supervised programme
Patients who want the convenience of once-weekly injection — a practical dosing schedule for patients managing busy professional or travel schedules
Those who want safe, systematic weight reduction under physician supervision with structured titration, regular monitoring, and transparent communication about progress and expectations
Those without contraindications — Wegovy is not appropriate for patients with a history of medullary thyroid carcinoma, or for pregnant or breastfeeding patients; this is assessed at consultation
Meet the Physician at Vellicell Clinic
|
Dr. Geon Kim, MD |
Dr. Kim Geon — Chief Director MD, Korea University College of Medicine | Resident, Korea University Medical Center | Former Chief Director, Maypure Clinic (Suji) | Member, Korean Society for Laser Dermatology and Hair · Korean Filler Society · Korean Lifting Society
Dr. Kim conducts the full consultation — evaluating BMI, health status, comorbid conditions, thyroid history, and current medications — before any prescription is issued. Starting dose, titration schedule, and monitoring frequency are determined individually. No prescription is issued without physician assessment, and no dosing decision is made without physician review of the patient's ongoing response.
How Wegovy Works: GLP-1 Receptor Mechanism
Appetite Center Signaling: Semaglutide binds to GLP-1 receptors in the brain's hypothalamic appetite center, transmitting sustained satiety signals that reduce hunger and naturally lower food intake. Unlike dietary willpower-based approaches, this physiological satiety signal operates continuously between meals — reducing the hunger-driven eating patterns that undermine conventional dieting.
Blood Sugar Regulation: GLP-1 receptor activation promotes glucose-dependent insulin secretion from the pancreas — releasing insulin in response to food intake — while simultaneously suppressing glucagon, the hormone that raises blood sugar between meals. The combined effect stabilizes post-meal blood sugar and supports overall glycemic control, making Wegovy particularly relevant for patients with pre-diabetes, type 2 diabetes, or elevated fasting glucose.
Metabolic Health Benefits: Beyond appetite and blood sugar, Wegovy's GLP-1 mechanism supports broader metabolic health improvements — including lipid metabolism and cardiovascular risk factor reduction — that extend the clinical benefit of the weight management programme beyond weight reduction alone.
Wegovy Prescription Process at Vellicell Clinic

Physician Consultation and Health Assessment — Your physician conducts a detailed evaluation of BMI, health status, comorbid conditions, thyroid history, pregnancy status, and current medications; candidacy is confirmed and contraindications are ruled out before any prescription is issued
Starting Dose Prescription — Treatment begins at 0.25mg once weekly; your physician explains the titration schedule, expected initial effects, and how to recognize and report adverse reactions
Stepwise Dose Titration — Dose is increased gradually according to individual tolerability and response; titration decisions are made by the physician based on monitoring data — never self-adjusted
Regular Follow-Up Monitoring — Scheduled return visits assess weight change, blood sugar response, gastrointestinal tolerability, and overall programme progress; adjustments are made based on objective clinical assessment
Lifestyle Integration Guidance — Wegovy is most effective when combined with appropriate dietary and lifestyle habits; your physician advises on how to integrate the prescription programme with your existing routine for optimal results
Expected Results, Safety, and Important Considerations
Wegovy's clinical evidence supports meaningful weight reduction when used as prescribed alongside appropriate lifestyle habits. Blood sugar stabilization, lipid metabolism improvement, and cardiovascular risk reduction develop alongside weight loss for patients with relevant comorbid conditions. Results vary by individual health profile, adherence, and lifestyle factors.
Common early side effects include nausea, vomiting, diarrhea, and other gastrointestinal discomfort — typically most prominent during dose escalation and manageable through the stepwise titration approach used at Vellicell. These effects generally reduce as the body adjusts to each dose level. Wegovy is contraindicated in patients with a history of medullary thyroid carcinoma and in pregnant or breastfeeding patients — both are assessed at consultation before any prescription is issued.
Self-adjustment of dosing outside physician guidance is not safe and is not supported at Vellicell. Persistent abdominal pain, severe dizziness, or unusual reactions during treatment should prompt an immediate clinic visit. Wegovy is a medical treatment requiring ongoing physician oversight throughout the prescription period — not a standalone injectable administered without supervision.
Why Choose Vellicell Clinic for Wegovy Prescription?

Wegovy at Vellicell is prescribed only by physician directors who have conducted a full individual health assessment — confirming candidacy, ruling out contraindications, and designing a titration and monitoring programme appropriate for each patient's specific health profile. The clinic's private, physician-led model means every Wegovy consultation is conducted 1:1 with one of the two director physicians, with complete medical transparency and no delegation to non-physician staff.
For international patients, Vellicell's multilingual consultation capability in English, Chinese, Japanese, and Thai ensures that health history, medication guidance, titration expectations, and monitoring requirements are fully understood regardless of language background. The clinic operates every day of the year — including Sundays and public holidays — supporting the scheduling requirements of patients managing ongoing once-weekly injection programmes.
Physician-only prescription — Wegovy issued exclusively following full health assessment by MD-qualified specialist directors
Conservative stepwise titration — starts at 0.25mg with physician-directed dose escalation based on individual tolerability monitoring
Contraindication screening — thyroid history, pregnancy status, and comorbid conditions assessed before prescription
Once-weekly convenience — practical dosing schedule supporting sustained programme adherence for busy or travelling patients
Patient Perspectives
Weight and Metabolic Health Patient, 50s
Managing both excess weight and elevated blood sugar despite sustained dietary effort, this patient consulted Dr. Kim for a prescription programme that could address both concerns simultaneously. Following a full health assessment confirming Wegovy candidacy, a conservative titration programme was initiated. Progressive weight reduction and improved blood sugar stability developed over the following months, with the once-weekly injection schedule fitting comfortably into his professional routine.
Diet-Resistant Weight Management Patient, 40s
After reaching a sustained plateau despite consistent dietary modification, this patient consulted Dr. Kim for a physiological intervention. Health assessment confirmed BMI and comorbidity criteria for Wegovy candidacy. The appetite regulation effect of the GLP-1 mechanism reduced the persistent hunger that had previously undermined dietary adherence, supporting more consistent and sustainable progress toward her weight management goals through the monitored programme.
Begin Your Wegovy Programme at Vellicell Clinic
Weight resistance driven by physiological appetite dysregulation and metabolic inefficiency responds to physiological solutions. Wegovy's GLP-1 semaglutide mechanism addresses appetite, blood sugar, and metabolic health simultaneously — under physician supervision that ensures safe, individually titrated dosing and structured ongoing monitoring. If diet and exercise alone have not produced the results your health requires, Vellicell is ready to assess whether Wegovy is the appropriate next step for your individual health profile.
\[Book Your Wegovy Consultation Today — Speak Directly with a Physician Director\]
Multilingual support available in English, Chinese, Japanese, and Thai. Open daily, including Sundays and public holidays.
Other Services
Explore additional treatments offered by our specialists.
Wegovy
Wegovy (semaglutide) is a prescription injectable medication for obesity treatment classified as a GLP-1 (glucagon-like peptide-1) receptor agonist.
Learn More
Volnewmer Lifting
Volnewmer is a non-surgical radiofrequency lifting treatment that delivers 6.78MHz monopolar RF thermal energy directly to the dermis, inducing tissue coagulation and triggering a collagen regeneration response.
Learn More
Ultherapy Prime
Ultherapy Prime is an advanced non-surgical lifting treatment that uses focused ultrasound energy to target the SMAS layer.
Learn More
